Summer Street is boosting its price target on Ligand Pharmaceuticals (Nasdaq: LGND) from $69 up to $78 following Q4 results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Cantor Fitzgerald Negative on Ligand Pharma (LGND) Reaction Post-Earnings February 12, 2014 9:13 AM Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts AheadFebruary 12, 2014 7:23 AM Ligand Pharma (LGND) Tops Q4 EPS by 16c; Issues Light Q1 OutlookFebruary 11, 2014 8:32 AM